title: Long-term results of bone marrow transplantation for patients with AML, ALL and CML prepared with single dose total body irradiation of 500 cGy delivered with a high dose rate.
abstract: One hundred and sixty-six patients between the ages of 12 and 48 years with acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL) or chronic myelogenous leukemia (CML) underwent allogeneic bone marrow transplantation following single fraction total body irradiation (TBI) of 500 cGy from a cobalt source. Patients also received one of three chemotherapeutic regimens according to their diagnosis or disease status at time of transplant. The median follow-up was 67 months with a range of 33-120 months. The actuarial 5-year event-free survival (EFS) for the subgroup of patients with good risk disease (first complete remission AML and ALL or first chronic phase CML) was 43% with an actuarial relapse rate at 5 years of 26%. Patients with poor risk disease (other than first remission AML and ALL or other than first chronic phase CML) had an EFS at 5 years of 15% with a relapse rate of 62%. Disease status at the time of transplantation was the most important factor predicting outcome in this patient population. We conclude that preparation of good risk patients with chemotherapy and single fraction TBI of 500 cGy at a dose rate of 42-91 cGy/min resulted in EFS and relapse rates similar to those observed by centers using fractionated radiotherapy schedules, without a concomitant increase in toxicity, in particular interstitial pneumonitis and cataracts.
authors.affiliation: Ontario Cancer Institute, Department of Medicine, University of Toronto, Canada.
authors.forename: G M
authors.initials: GM
authors.lastname: Fyles
authors.forename: H A
authors.initials: HA
authors.lastname: Messner
authors.forename: G
authors.initials: G
authors.lastname: Lockwood
authors.forename: J E
authors.initials: JE
authors.lastname: Curtis
authors.forename: W
authors.initials: W
authors.lastname: Rider
authors.forename: M D
authors.initials: MD
authors.lastname: Minden
authors.forename: J M
authors.initials: JM
authors.lastname: Meharchand
authors.forename: J
authors.initials: J
authors.lastname: Lipton
authors.forename: D
authors.initials: D
authors.lastname: Tritchler
authors.forename: J
authors.initials: J
authors.lastname: Van Dyk
mesh_terms: D000293:Adolescent; D000328:Adult; D016026:Bone Marrow Transplantation / Q000009:adverse effects; D002386:Cataract / Q000453:epidemiology / Q000209:etiology; D002648:Child; D003131:Combined Modality Therapy; D004307:Dose-Response Relationship, Radiation; D005260:Female; D006084:Graft Rejection; D006086:Graft vs Host Disease / Q000453:epidemiology; D006801:Humans; D015994:Incidence; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000401:mortality / Q000532:radiotherapy* / Q000601:surgery*; D015470:Leukemia, Myeloid, Acute / Q000401:mortality / Q000532:radiotherapy* / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000401:mortality / Q000532:radiotherapy* / Q000601:surgery*; D011658:Pulmonary Fibrosis / Q000453:epidemiology / Q000209:etiology; D013997:Time Factors; D014916:Whole-Body Irradiation